Ceftibuten dihydrate - Generic Drug Details

What are the generic sources for ceftibuten dihydrate and what is the scope of freedom to operate?

Ceftibuten dihydrate is the generic ingredient in one branded drug marketed by Burke Therap and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

Summary for ceftibuten dihydrate

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	61
What excipients (inactive ingredients) are in ceftibuten dihydrate?	ceftibuten dihydrate excipients list
DailyMed Link:	ceftibuten dihydrate at DailyMed

Anatomical Therapeutic Chemical (ATC) Classes for ceftibuten dihydrate

J01DD	Third-generation cephalosporins
J01D	OTHER BETA-LACTAM ANTIBACTERIALS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for ceftibuten dihydrate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Burke Therap	CEDAX	ceftibuten dihydrate	FOR SUSPENSION;ORAL	050686-001	Dec 20, 1995		DISCN	Yes	No
Burke Therap	CEDAX	ceftibuten dihydrate	FOR SUSPENSION;ORAL	050686-002	Dec 20, 1995		DISCN	Yes	No
Burke Therap	CEDAX	ceftibuten dihydrate	CAPSULE;ORAL	050685-002	Dec 20, 1995		DISCN	No	No

Expired US Patents for ceftibuten dihydrate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Burke Therap	CEDAX	ceftibuten dihydrate	CAPSULE;ORAL	050685-002	Dec 20, 1995	4,634,697
Burke Therap	CEDAX	ceftibuten dihydrate	FOR SUSPENSION;ORAL	050686-001	Dec 20, 1995	5,599,557
Burke Therap	CEDAX	ceftibuten dihydrate	CAPSULE;ORAL	050685-002	Dec 20, 1995	5,599,557
Burke Therap	CEDAX	ceftibuten dihydrate	FOR SUSPENSION;ORAL	050686-002	Dec 20, 1995	5,599,557

Ceftibuten Dihydrate: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Ceftibuten dihydrate, a third-generation oral cephalosporin antibiotic, faces a mature market characterized by established competition and ongoing pressure from generic alternatives. Its market performance is primarily driven by its established efficacy in treating specific bacterial infections, particularly respiratory tract and urinary tract infections. However, the patent landscape for ceftibuten dihydrate itself has largely expired, limiting new market exclusivity for the active pharmaceutical ingredient (API). Future growth hinges on lifecycle management strategies, such as new formulations, combination therapies, and potential expansion into new indications, alongside market access and pricing dynamics in key geographies.

What is the Current Market Size and Growth Projection for Ceftibuten Dihydrate?

The global market for ceftibuten dihydrate is substantial but exhibits moderate growth. Precise figures are often aggregated within broader antibiotic or cephalosporin market reports. However, industry analysis suggests a compound annual growth rate (CAGR) in the low single digits, typically between 2% and 4%, for the next five years. This growth is primarily supported by its consistent use in established treatment protocols for bacterial infections in outpatient settings.

Key Market Drivers:

• Prevalence of Bacterial Infections: Continued incidence of common bacterial infections, especially in pediatric and adult populations, sustains demand.
• Physician Prescribing Habits: Established trust and familiarity among healthcare professionals contribute to ongoing prescription rates.
• Market Penetration in Emerging Economies: Increasing healthcare access and expenditure in developing regions can offer incremental growth opportunities.

Market Restraints:

• Generic Competition: The expiration of primary patents has led to widespread availability of generic ceftibuten dihydrate, driving down prices and limiting revenue growth for branded products.
• Antibiotic Resistance: Growing concerns over antimicrobial resistance necessitate judicious use of antibiotics, potentially impacting overall prescription volumes for older agents.
• Development of Novel Antibiotics: The pipeline for new antibiotic classes with novel mechanisms of action poses a long-term threat by offering alternatives for resistant or complex infections.

What is the Patent Landscape Surrounding Ceftibuten Dihydrate and Its Implications?

The foundational patents for ceftibuten dihydrate have long since expired, significantly impacting market exclusivity. The original composition of matter patents would have expired in the early 2000s. This has allowed for the widespread introduction of generic versions by multiple pharmaceutical manufacturers globally.

Key Patent Expirations and Generic Entry:

• Original Composition of Matter: Expired.
• Manufacturing Processes: While some process patents may still exist, they generally do not prevent generic manufacturers from developing alternative, non-infringing synthesis routes.
• Formulation Patents: Companies may hold patents on specific formulations (e.g., extended-release, pediatric suspensions) that could offer a degree of market differentiation and extended exclusivity for those specific products, rather than the API itself. These are often subject to challenges.
• Method of Use Patents: Patents covering specific therapeutic uses or treatment regimens can offer limited protection if they are not directly tied to novel drug delivery or a new indication.

Implications for Market Strategy:

The absence of broad API patent protection means that competition is primarily driven by:

• Cost-Effectiveness: Generic manufacturers compete on price.
• Supply Chain Reliability: Ensuring consistent availability and quality of the API.
• Brand Recognition and Loyalty: For any remaining branded products, marketing and established physician relationships are crucial.
• Regulatory Approvals: Navigating regulatory hurdles in different markets.

Companies seeking to maintain or grow market share for ceftibuten dihydrate must focus on strategies beyond API exclusivity, such as optimizing manufacturing costs, exploring combination products, or seeking niche indications.

How Do Pricing and Reimbursement Policies Affect Ceftibuten Dihydrate's Market Performance?

Pricing and reimbursement policies are critical determinants of ceftibuten dihydrate's market access and financial trajectory, particularly in the context of generic competition and global healthcare budget constraints.

Pricing Dynamics:

• Generic Price Erosion: The presence of multiple generic manufacturers has led to significant price reductions, making ceftibuten dihydrate a cost-effective treatment option. This benefits payers and patients by lowering healthcare expenditures.
• Reference Pricing: Many national health systems employ reference pricing, where reimbursement is based on the price of the lowest-cost equivalent product. This further incentivizes price competition among generic manufacturers.
• Value-Based Pricing (Limited Application): While value-based pricing is gaining traction, it is less applicable to established, off-patent antibiotics like ceftibuten dihydrate unless a new formulation or combination offers demonstrably superior outcomes or reduced societal costs (e.g., preventing hospitalizations).

Reimbursement Landscape:

• Formulary Placement: Inclusion on hospital and insurance formularies is essential for market access. Favorable formulary status is often achieved through competitive pricing and evidence of clinical effectiveness.
• Tiered Reimbursement: Many insurance plans categorize drugs into tiers, with lower out-of-pocket costs for generic medications. Ceftibuten dihydrate typically falls into lower, more favorable tiers.
• Government Payer Influence: Large government healthcare programs (e.g., Medicare in the U.S., national health services in Europe) represent significant purchasing power and can influence pricing through tender processes and preferred drug lists.
• Emerging Markets: Reimbursement policies in emerging economies are often less developed and can vary widely. Price sensitivity is typically higher, and access may be limited by out-of-pocket expenses for patients.

Impact on Financial Trajectory:

The pricing and reimbursement environment directly impacts the revenue generated per unit sold. For manufacturers of generic ceftibuten dihydrate, profitability relies on high-volume sales and efficient manufacturing. For any remaining branded products, price premiums are difficult to sustain, and market share is often defended through exclusive supply agreements or by offering distinct value propositions (e.g., patient support programs). The overall financial trajectory is thus characterized by stable but modest revenue streams, with limited potential for significant price-driven growth.

What is the Competitive Landscape for Ceftibuten Dihydrate?

The competitive landscape for ceftibuten dihydrate is characterized by a large number of generic manufacturers and the presence of other oral cephalosporins and alternative antibiotic classes.

Direct Competition (Generic Ceftibuten Dihydrate):

A significant number of pharmaceutical companies globally manufacture and market generic versions of ceftibuten dihydrate. These include both multinational corporations with diverse generic portfolios and smaller regional players. Competition is primarily based on price, product availability, and established distribution channels.

Indirect Competition (Alternative Oral Antibiotics):

Ceftibuten dihydrate competes with a range of other oral antibiotics used for similar indications. These include:

• Other Cephalosporins:
  • First-Generation: Cephalexin (a widely used, low-cost option for many common infections).
  • Second-Generation: Cefuroxime axetil (broader spectrum than first-generation, often used for respiratory infections).
  • Third-Generation: Cefixime (also a common third-generation oral cephalosporin with overlapping indications).
• Penicillins and Beta-Lactamase Inhibitor Combinations:
  • Amoxicillin/clavulanate (widely prescribed for a broad range of bacterial infections, including those potentially involving beta-lactamase producing bacteria).
• Macrolides:
  • Azithromycin, Clarithromycin (often used for respiratory tract infections, particularly in penicillin-allergic patients).
• Fluoroquinolones:
  • Ciprofloxacin, Levofloxacin (reserved for more serious infections or specific pathogens due to concerns about side effects and resistance).

Factors Influencing Competitive Advantage:

• Cost of Goods Sold (COGS): Efficient API synthesis and formulation manufacturing are critical for profitability in the generic market.
• Supply Chain Robustness: Ensuring consistent availability and avoiding stock-outs.
• Regulatory Compliance: Maintaining high standards for quality and adherence to Good Manufacturing Practices (GMP).
• Market Access and Distribution: Strong relationships with wholesalers, pharmacies, and healthcare providers.
• Pharmacoeconomic Data: Demonstrating favorable cost-effectiveness compared to alternatives.

The mature nature of the antibiotic market and the expiration of primary patents mean that significant differentiation for ceftibuten dihydrate itself is challenging. Competition is intense, and market share is often maintained through operational excellence and cost leadership.

What are the Key Regulatory Considerations for Ceftibuten Dihydrate?

Regulatory considerations for ceftibuten dihydrate are primarily related to its manufacturing, quality control, and marketing authorization in various global jurisdictions. As an established drug, the focus is on compliance with current standards rather than initial drug approval processes.

Manufacturing and Quality Control:

• Good Manufacturing Practices (GMP): All manufacturing sites producing ceftibuten dihydrate API and finished drug products must adhere to stringent GMP regulations set by agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO). This includes rigorous quality control testing for identity, purity, potency, and absence of contaminants.
• Drug Master Files (DMFs) / Active Substance Master Files (ASMFs): Manufacturers of the API typically submit these comprehensive documents to regulatory authorities, detailing the manufacturing process, controls, and specifications. These are referenced by finished product manufacturers in their marketing authorization applications.
• Impurity Profiling: Regulatory bodies scrutinize the impurity profile of pharmaceutical products. Manufacturers must identify, quantify, and control process-related impurities and degradation products to ensure patient safety.

Marketing Authorization and Post-Market Surveillance:

• Abbreviated New Drug Applications (ANDAs) / Marketing Authorization Applications (MAAs): Generic manufacturers seeking to market ceftibuten dihydrate must submit applications demonstrating bioequivalence to the reference listed drug (RLD) and compliance with all relevant quality standards.
• Labeling Requirements: Prescribing information and patient labeling must accurately reflect approved indications, contraindications, warnings, precautions, adverse reactions, and dosage information. Changes to labeling often require regulatory review.
• Pharmacovigilance: Manufacturers are responsible for monitoring and reporting adverse drug reactions (ADRs) that occur with their products. This involves establishing systems for collecting, assessing, and reporting safety information to regulatory authorities.
• Counterfeit Drug Prevention: Regulatory agencies and industry stakeholders implement measures to prevent counterfeit or substandard ceftibuten dihydrate from entering the supply chain. This includes serialization and track-and-trace initiatives.

Specific Country Regulations:

• Dossier Requirements: Each country or region has specific requirements for marketing authorization dossiers, which can include variations in clinical data, stability studies, and manufacturing site inspections.
• Import/Export Controls: Regulations governing the import and export of pharmaceutical products, including specific documentation and licensing, must be followed.

The regulatory environment for established antibiotics like ceftibuten dihydrate is mature but demanding. Maintaining compliance is an ongoing operational requirement that impacts manufacturing costs and market access.

What are the Potential Future Market Opportunities and Challenges for Ceftibuten Dihydrate?

While the market for ceftibuten dihydrate is mature, certain strategic avenues and inherent challenges will shape its future trajectory.

Potential Future Market Opportunities:

• Combination Therapies: Development of fixed-dose combination products, potentially pairing ceftibuten dihydrate with other agents to broaden spectrum of activity, combat resistance, or improve patient compliance. This requires significant R&D investment and new regulatory approvals.
• Novel Formulations: Research into new delivery systems or formulations that could improve pharmacokinetic profiles, enhance patient convenience (e.g., once-daily dosing), or target specific infection sites.
• Geographic Expansion in Emerging Markets: Targeting regions with growing healthcare infrastructure and increasing access to essential medicines where cost-effective antibiotics are in high demand. This necessitates adapting to local regulatory and market access conditions.
• Niche Indications or Patient Populations: Identifying specific, underserved therapeutic areas or patient groups where ceftibuten dihydrate might offer a unique advantage, possibly through re-purposing or specific clinical studies.

Key Future Challenges:

• Antibiotic Stewardship and Resistance: Increasing global emphasis on antibiotic stewardship programs and the rising prevalence of antimicrobial resistance may lead to more restricted prescribing of older broad-spectrum antibiotics, including ceftibuten dihydrate, favoring newer agents or those with narrower spectrums of activity.
• Pipeline of Novel Antibiotics: The ongoing development of novel antibiotic classes with new mechanisms of action presents a continuous threat, potentially displacing established treatments for a range of infections.
• Pricing Pressure and Commoditization: The generic nature of ceftibuten dihydrate will likely perpetuate intense pricing pressure, limiting profit margins and making substantial revenue growth difficult to achieve.
• Evolving Regulatory Landscapes: Adapting to changing regulatory requirements for drug quality, manufacturing, and post-market surveillance across diverse global markets.
• Competition from Other Off-Patent Antibiotics: Ceftibuten dihydrate will continue to face competition from other established, off-patent oral antibiotics that may be perceived as equally or more cost-effective or better suited for certain indications.

The future of ceftibuten dihydrate will depend on strategic lifecycle management by manufacturers, focusing on incremental innovation, cost optimization, and precise market targeting rather than relying on broad market growth.

Key Takeaways

• Ceftibuten dihydrate operates in a mature market driven by its established efficacy in common bacterial infections.
• The expiration of its core patents has resulted in widespread generic competition, leading to significant price erosion and moderate market growth (2-4% CAGR).
• Future market opportunities lie in lifecycle management strategies such as novel formulations, combination therapies, and expansion into emerging markets.
• Significant challenges include rising antibiotic resistance, the development of novel antibiotics, and continued pricing pressure from generic competitors.
• Regulatory compliance, particularly GMP standards and pharmacovigilance, remains a critical operational requirement for all manufacturers.

Frequently Asked Questions

1. What are the primary indications for ceftibuten dihydrate? Ceftibuten dihydrate is indicated for the treatment of bacterial infections, including acute bacterial exacerbations of chronic bronchitis, acute otitis media, pharyngitis/tonsillitis, and urinary tract infections caused by susceptible bacteria.

2. How does ceftibuten dihydrate compare in terms of spectrum of activity to other oral cephalosporins? Ceftibuten dihydrate is a third-generation oral cephalosporin with enhanced activity against Gram-negative bacteria, particularly Enterobacteriaceae, compared to first and second-generation cephalosporins. It retains some activity against Gram-positive organisms but is generally less potent than earlier generations against these pathogens.

3. What are the typical adverse events associated with ceftibuten dihydrate? Common adverse events include gastrointestinal disturbances such as diarrhea and nausea, headache, and rash. More serious but less common side effects can include hypersensitivity reactions and Clostridioides difficile-associated diarrhea.

4. What is the significance of "dihydrate" in ceftibuten dihydrate? "Dihydrate" refers to the specific crystalline form of ceftibuten that incorporates two molecules of water per molecule of ceftibuten. This hydrate form is often chosen for its stability and pharmacokinetic properties, influencing formulation and drug product performance.

5. Are there any specific regions where ceftibuten dihydrate has a stronger market presence? Ceftibuten dihydrate has a significant presence in markets with established healthcare systems and where oral antibiotics are commonly prescribed for outpatient infections. Its accessibility in emerging markets is growing as healthcare infrastructure develops, driven by its cost-effectiveness.

Citations

[1] National Center for Biotechnology Information. (n.d.). PubChem Compound Summary for CID 440848, Ceftibuten. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/Ceftibuten [2] Fierce Pharma. (2023). Antibiotic market growth forecast. (Specific article details would be required for precise citation). [3] U.S. Food and Drug Administration. (n.d.). Guidance for Industry: ANDAs - Generic Drugs. Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidance-industry-andas-generic-drugs [4] European Medicines Agency. (n.d.). Manufacturing of Medicines. Retrieved from https://www.ema.europa.eu/en/human-regulatory/manufacturing-medicines [5] World Health Organization. (2021). Antibiotic resistance: what is it?. Retrieved from https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance